Question:
I ask you if you know what are the exact pharmacological profiles for each of the SSRIs drugs.(sedating/stimulating properties,receptor bindings, selectivity or multiple neurotransmitters involved in mechanism of action, etc.) I’m curious about every drug i take, that’s why i ask that, thanks,. Luca Zoli Ceccaroni C.V.
You can look up specific medications at this site: www.rxlist.com Have fun! Nancy to email me, remove the Z. administrator/creator/moderator alt.med.fibromyalgia.recovery.info (moderated) alt.support.depression.manic.moderated
Response:
thanks Lynda:) Luca Zoli Ceccaroni C.V. – Hide quoted text — Show quoted text – I ask you if you know what are the exact pharmacological profiles for each of the SSRIs drugs.(sedating/stimulating properties,receptor bindings, selectivity or multiple neurotransmitters involved in mechanism of action, etc.) I’m curious about every drug i take, that’s why i ask that, thanks,. Luca Zoli Ceccaroni C.V.
Response:
I ask you if you know what are the exact pharmacological profiles for each of the SSRIs drugs.(sedating/stimulating properties,receptor bindings, selectivity or multiple neurotransmitters involved in mechanism of action, etc.) I’m curious about every drug i take, that’s why i ask that, thanks,. Luca Zoli Ceccaroni C.V.
Response:
Hi Luca, and Welcome to ASDMM, I ask you if you know what are the exact pharmacological profiles for each of the SSRIs drugs.(sedating/stimulating properties,receptor bindings, selectivity or multiple neurotransmitters involved in mechanism of action, etc.) I’m curious about every drug i take, that’s why i ask that, thanks,.
here is some information: http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed& list_uids=10086481&dopt=Abstract 1: J Clin Psychiatry 1999;60 Suppl 4:33-8 SSRIs and SNRIs: broad spectrum of efficacy beyond major depression. Gorman JM, Kent JM Department of Clinical Psychobiology, New York State Psychiatric Institute, College of Physicians and Surgeons of Columbia University, New York 10032, USA. Originally studied and introduced for the treatment of depression, the selective serotonin reuptake inhibitors (SSRIs) and serotonin/norepinephrine reuptake inhibitors (SNRIs) have proven effective for a broad range of psychiatric illnesses, including several anxiety disorders, bulimia, and dysthymia. These drugs have in common important effects on the serotonergic (5-HT) neurotransmission system, which is involved in mediating a substantial number of important functions, including mood, aggression, sexual behavior, and pain. In addition, some of the new antidepressants, like venlafaxine/venlafaxine XR, also have effects on the noradrenergic neurotransmission system, which also appears important in mood and anxiety disorders. These new drugs, because of their specificity for the serotonin and norepinephrine reuptake proteins, lack most of the adverse side effects of tricyclic antidepressants and monoamine oxidase inhibitors. Consequently, in addition to being the usual first-line treatments for major depression, they are also first-line for panic disorder, obsessive-compulsive disorder, social phobia, posttraumatic stress disorder, and bulimia. They may also be the best medication treatments for dysthymia and generalized anxiety disorder. Further advances in psychopharmacology will be driven by discoveries from brain imaging and molecular biological research. http://www.biopsychiatry.com/new.htm SNaRIs, NaSSAs, and NaRIs: new agents for the treatment of depression by Kent JM New York State Psychiatric Institute, Unit 41, New York, NY 10032, USA. Lancet 2000 Mar 11; 355(9207):911-8 ABSTRACT A major goal of antidepressant development is to improve on preceding drug classes with agents with greater specificity (and therefore fewer unwanted side-effects) and with more rapid onset of antidepressant action. To this end, four antidepressants with significantly distinct pharmacological characteristics have been recently introduced: venlafaxine, nefazodone, mirtazapine, and reboxetine. Venlafaxine is the first antidepressant in a new drug class referred to as the serotonin noradrenergic reuptake inhibitors (SNaRIs). Nefazodone is a weaker serotonin and norepinephrine reuptake inhibitor, but a potent serotonin 5-HT2 receptor antagonist. Mirtazapine is a potent antagonist of central 2alpha-adrenergic autoreceptors, and heteroreceptors and is an antagonist of serotonin 5-HT2 and 5-HT3 receptors. The result of these actions is to increase both noradrenergic and specific (5-HT1) serotonergic transmission, and mirtazapine has therefore been termed a noradrenergic and specific serotonergic antidepressant (NaSSA). Reboxetine is the first selective noradrenaline reuptake inhibitor (NaRI) to be introduced since the tricyclics, and lacks immediate serotonergic effects. Select any of the following topics after going to this site: http://www.biopsychiatry.com/new.htm TCAs SSRIs NARIs RIMAs Options SSRIs/SNRIs 21st century Sigma ligands Plato v Aristotle Antidepressants New antidepressants Future pharmacotherapies The monoamine hypothesis LyndaNP Reality isn’t the way you wish things to be, nor the way they appear to be, but the way they actually are. – Robert J. Ringer
If you like this post and would like to receive updates from this blog, please subscribe our feed.